Pyridostigmine

# Pyridostigmine ## Overview - **Classification**: Reversible Acetylcholinesterase Inhibitor - **Mechanism**: Inhibits the breakdown of acetylcholine (ACh) by acetylcholinesterase, increasing ACh concentration at neuromuscular junctions and autonomic synapses. ## Primary Indications 1. **Myasthenia Gravis (MG)** - Symptomatic treatment of muscle weakness. 2. **Reversal of Neuromuscular Blockade** - Reverses effect of nondepolarizing neuromuscular blocking agents. 3. **Postoperative Paralytic Ileus/Urinary Retention** - Stimulation of bowel/bladder motility (less common). ## Adult Dosing ### Standard Dosing **Myasthenia Gravis (Oral)** - **Dose**: **30-60 mg** - **Frequency**: Every 3-8 hours, adjusted to patient response. - **Route**: Oral (immediate release tablets, syrup) - **Maximum Dose**: Typically **300-600 mg/day**. - **Special Consideration**: **Extended-release (SR)**: **180 mg** 1-2 times daily, administered at least 6 hours apart. **Myasthenia Gravis (Parenteral)** - **Dose**: **2 mg** (IM or slow IV) - **Frequency**: Every 2-3 hours. - **Route**: Intramuscular (IM) or Intravenous (IV) - **Special Consideration**: Parenteral dose is approx. 1/30th of oral dose. **Reversal of Neuromuscular Blockade** - **Dose**: **0.1-0.25 mg/kg** IV - **Frequency**: Single dose. - **Route**: Intravenous (IV) - **Maximum Dose**: **10 mg** total dose. - **Special Consideration**: Administer with an anticholinergic (e.g., glycopyrrolate **0.2 mg** for every **1 mg** pyridostigmine) to mitigate muscarinic effects. **Postoperative Paralytic Ileus/Urinary Retention** - **Dose**: **2 mg** - **Frequency**: Every 2-3 hours until function returns. - **Route**: Intramuscular (IM) or Intravenous (IV) ### Dose Adjustments - **Renal Impairment**: Reduce dose due to renal elimination. - CrCl 10-50 mL/min: Administer **50% of dose** or extend interval. - CrCl <10 mL/min: Administer **25% of dose** or extend interval. - **Hepatic Impairment**: No specific adjustments, primarily renal elimination. - **Elderly Patients**: Start at the lower end of the dosing range and titrate slowly; monitor for increased sensitivity and renal function decline. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Limited data. If used, consider **1 mg/kg/day** in 6-8 divided doses. - **Frequency**: Every 3-4 hours. - **Maximum**: Titrate cautiously. - **Special Notes**: Close monitoring for cholinergic crisis is crucial due to narrow therapeutic index. Oral solution is preferred for precise dosing. ### Infants (1-12 months) - **Dose**: Initial **1 mg/kg/day** in 6-8 divided doses. - **Frequency**: Every 3-4 hours. - **Maximum**: Titrate up to **7 mg/kg/day** based on response and tolerability. - **Special Notes**: Start low and titrate carefully. ### Children (1-12 years) - **Myasthenia Gravis (Oral)** - **Dose**: Initial **1 mg/kg/day** in 3-6 divided doses. - **Frequency**: Every 4-8 hours. - **Maximum**: Typical maintenance **7 mg/kg/day**, not to exceed **300 mg/day**. - **Reversal of Neuromuscular Blockade (IV)** - **Dose**: **0.1-0.25 mg/kg** IV. - **Maximum**: **10 mg** total dose. - **Special Notes**: Administer with an anticholinergic like glycopyrrolate. ### Adolescents (13-18 years) - **Dose**: Generally follows adult dosing guidelines. Start with **30-60 mg** 3-8 times/day. - **Maximum**: **600 mg/day**. - **Special Notes**: Adjust based on clinical response and side effects. ## Safety Information ### Contraindications - **Absolute**: Mechanical obstruction of the gastrointestinal or urinary tract. - **Absolute**: Hypersensitivity to pyridostigmine or bromides. - **Relative**: Bradycardia, hypotension, peptic ulcer, asthma, COPD, hyperthyroidism, seizure disorder. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, vomiting, diarrhea, abdominal cramps, increased salivation, increased bronchial secretions, miosis, sweating. - **Common (1-10%)**: Bradycardia, muscle cramps, weakness, fasciculations. - **Serious but Rare**: Cholinergic crisis (severe muscle weakness, respiratory paralysis), cardiac arrhythmias (e.g., AV block, asystole). ### Key Drug Interactions - **Corticosteroids**: May initially worsen MG symptoms, then improve. Monitor MG status. - **Aminoglycosides, Local Anesthetics**: Can antagonize pyridostigmine's effect. Monitor for MG exacerbation. - **Beta-blockers**: May potentiate bradycardia. Monitor heart rate closely. - **Anticholinergics (e.g., Atropine, Glycopyrrolate)**: Can reduce therapeutic effects if given in high doses; used to counteract muscarinic side effects. ## Monitoring & Follow-up - **Before Treatment**: Baseline vital signs (HR, BP), renal function. - **During Treatment**: Monitor clinical response (muscle strength, ability to chew, swallow, breathe), vital signs, and adverse effects (e.g., gastrointestinal distress, excessive secretions). - **Clinical Signs**: Watch for signs of underdosing (increased weakness, fatigue) vs. overdosing (cholinergic crisis: profound weakness, slurred speech, dyspnea, increased secretions, bradycardia). ## Clinical Pearls - 💡 **Tip 1**: Administer oral doses **30-45 minutes before meals** to minimize dysphagia and improve drug absorption. - 💡 **Tip 2**: Dosing for Myasthenia Gravis is highly individualized; titrate to achieve optimal muscle strength with minimal side effects. - 💡 **Tip 3**: Distinguish between myasthenic crisis (underdosing, requires more drug) and cholinergic crisis (overdosing, requires drug discontinuation/atropine). Edrophonium test can help. - 💡 **Tip 4**: Extended-release tablets must be **swallowed whole** and not crushed or chewed. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.